CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Ann Arbor, Michigan, United States and 262 other locations
aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor...
Phase 1, Phase 2
Detroit, Michigan, United States and 21 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....
Phase 1, Phase 2
Maumee, Ohio, United States and 20 other locations
care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 20 other locations
To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in a complex colorectal procedure such as low a...
Detroit, Michigan, United States and 8 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 85 other locations
test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer...
Phase 1, Phase 2
Detroit, Michigan, United States and 18 other locations
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose ...
Phase 1
Farmington Hills, Michigan, United States of America and 13 other locations
tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors...
Phase 1, Phase 2
Detroit, Michigan, United States and 52 other locations
of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors...
Phase 1, Phase 2
Detroit, Michigan, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal